Invasive pneumococcal disease: Association between serotype, clinical presentation and lethality (Q51165807)

31 March 2018

title

Invasive pneumococcal disease: association between serotype, clinical presentation and lethality (English)

1 reference

31 March 2018

Invasive pneumococcal disease: Association between serotype, clinical presentation and lethality (English)

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

4 December 2024

author name string

Amai Varela González

2

1 reference

31 March 2018

María Ascensión Ordobás Gavín

3

1 reference

31 March 2018

Fernando Martín Martínez

4

1 reference

31 March 2018

Natividad García Marín

5

1 reference

31 March 2018

Belén Ramos Blázquez

6

1 reference

31 March 2018

Juan Carlos Sanz Moreno

7

1 reference

31 March 2018

M. Angeles Gutiérrez Rodríguez

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21683112

4 December 2024

language of work or name

English

0 references

publication date

15 June 2011

1 reference

31 March 2018

full work available at URL

https://api.elsevier.com/content/article/PII:S0264410X11008656?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

https://api.elsevier.com/content/article/PII:S0264410X11008656?httpAccept=text/plain

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

4 December 2024

1 reference

31 March 2018

volume

29

1 reference

31 March 2018

issue

34

1 reference

31 March 2018

page(s)

5740-5746

1 reference

31 March 2018

Pneumococcal disease surveillance in Europe

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

First report of Streptococcus pneumoniae serotype 6D isolates from invasive infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Epidemiological differences among pneumococcal serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Epidemiologic features of invasive pneumococcal disease in Belgian children: passive surveillance is not enough

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Burden of paediatric invasive pneumococcal disease in Europe, 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996–2006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Effectiveness of a 2 1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Emergence of Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes in the Era of 7-Valent Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Clonal and Capsular Types Decide Whether Pneumococci Will Act as a Primary or Opportunistic Pathogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

The paradox in pneumococcal serotypes: highly invasive does not mean highly lethal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Serotype distribution and susceptibility of Streptococcus pneumoniae isolates from pleural fluid in Spain from 1997 to 2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Pediatric parapneumonic empyema, Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Serotypes 1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Variation in incidence of pneumococcal and meningococcal disease across Europe

7 January 2021

7

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

Invasive pneumococcal disease in Australia, 2006

4 December 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.05.099

4 December 2024

Identifiers

1 reference

31 March 2018

1 reference

31 March 2018